Magali Vercauteren
Overview
Explore the profile of Magali Vercauteren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zumbrunn C, Remen L, Sager C, Grisostomi C, Stamm C, Krusi D, et al.
ChemMedChem
. 2025 Mar;
:e202401012.
PMID: 40071533
Galectin-3 (Gal-3), a β-galactoside-binding lectin, is implicated in diverse cellular functions ranging from immune response modulation to tissue homeostasis. Notably, increased Gal-3 expression has been linked to the progression of...
2.
Gehin M, Welford R, Garzotti M, Vercauteren M, Groenen P, Nayler O, et al.
Clin Pharmacol Ther
. 2018 Apr;
104(6):1260-1267.
PMID: 29663345
Serotonin (5-HT) is synthesized from dietary tryptophan (Trp) and plays an important role in numerous diseases of the central nervous system and periphery. Stable isotope tracers enable safe monitoring of...
3.
Vercauteren M, Trensz F, Pasquali A, Cattaneo C, Strasser D, Hess P, et al.
J Pharmacol Exp Ther
. 2017 Feb;
361(2):322-333.
PMID: 28223322
Endothelin (ET) receptor antagonists have been associated with fluid retention. It has been suggested that, of the two endothelin receptor subtypes, ET receptors should not be blocked, because of their...
4.
Welford R, Vercauteren M, Trebaul A, Cattaneo C, Eckert D, Garzotti M, et al.
Sci Rep
. 2016 Jul;
6:30059.
PMID: 27444653
The biogenic amine serotonin (5-HT) is a multi-faceted hormone that is synthesized from dietary tryptophan with the rate limiting step being catalyzed by the enzyme tryptophan hydroxylase (TPH). The therapeutic...
5.
Iglarz M, Landskroner K, Bauer Y, Vercauteren M, Rey M, Renault B, et al.
J Cardiovasc Pharmacol
. 2015 Aug;
66(5):457-67.
PMID: 26230396
Aims: We compared the efficacy of macitentan, a novel dual endothelin A/endothelin B receptor antagonist, with that of another dual endothelin receptor antagonist, bosentan, in a rat model of non-vasoreactive...
6.
Gomez E, Vercauteren M, Kurtz B, Ouvrard-Pascaud A, Mulder P, Henry J, et al.
J Mol Cell Cardiol
. 2012 Mar;
52(6):1257-64.
PMID: 22446161
Protein tyrosine phosphatase 1B (PTP1B) regulates tyrosine kinase receptor-mediated responses, and especially negatively influences insulin sensitivity, thus PTP1B inhibitors (PTP1Bi) are currently evaluated in the context of diabetes. We recently...
7.
Fang Y, Debunne M, Vercauteren M, Brakenhielm E, Richard V, Lallemand F, et al.
J Cardiovasc Pharmacol
. 2011 Nov;
59(3):260-7.
PMID: 22075752
Aims: Enhanced heart rate (HR) is a compensatory mechanism in chronic heart failure (CHF), preserving cardiac output, but at the cost of increased left ventricular (LV) oxygen consumption and impaired...
8.
Richard V, Vercauteren M, Gomez E, Thuillez C
Therapie
. 2009 Aug;
64(2):93-100.
PMID: 19664402
Heart failure is associated with endothelial dysfunction, characterized especially by a decreased nitric oxide (NO) production. The main consequences of this dysfunction appear to be: 1) at the coronary level,...
9.
Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, et al.
Eur Heart J
. 2008 Jul;
29(17):2171-9.
PMID: 18586661
Aims: Inhibition of aldosterone synthase, the key enzyme in aldosterone formation, could be an alternative strategy for mineralocorticoid-receptor antagonists in congestive heart failure (CHF), but its effect in CHF is...
10.
Vercauteren M, Remy E, Devaux C, Dautreaux B, Henry J, Bauer F, et al.
Circulation
. 2006 Nov;
114(23):2498-507.
PMID: 17101854
Background: Chronic heart failure (CHF) induces endothelial dysfunction characterized by a decrease in nitric oxide (NO) production in response to flow (flow-mediated dilatation [FMD]). Because activation of endothelial NO synthase...